Bicycle Therapeutics reported updated clinical results across its oncology pipeline, including a 45% overall response rate (ORR) for zelenectide pevedotin monotherapy and a 45% ORR for BT5528 6.5 mg/m2 every two weeks monotherapy, both in metastatic urothelial cancer. The company's cash and cash equivalents were $890.9 million as of September 30, 2024, excluding $31.7 million UK R&D tax credit received in October 2024, providing an expected financial runway into 2H 2027.